Ingevity (NGVT) opened 2026 with Q1 revenue of US$258 million and basic EPS of US$0.66, supported by net income excluding extra items of US$23.4 million and earnings from discontinued operations of US$36.4 million. The company has seen quarterly revenue move from US$340.1 million and EPS of a US$1.54 loss in Q1 2024 to US$284 million and EPS of US$0.56 in Q1 2025, landing at US$258 million and EPS of US$0.66 in Q1 2026, while trailing 12 month figures still reflect a loss, with basic EPS at a US$4.34 loss on US$1.18 billion in revenue. Overall, margins in the latest quarter point to a cleaner earnings profile, even as longer term profitability trends remain under pressure.

See our full analysis for Ingevity.

Next up is how these results line up against the widely followed narratives around Ingevity's growth prospects, profitability path, and risk profile, and where the data pushes back on those stories.

Trailing losses still heavy at US$156 million

• Over the last 12 months, Ingevity booked a net income loss excluding extra items of US$156 million on US$1.18b in revenue, even though Q1 2026 on its own showed net income excluding extra items of US$23.4 million.
• Analysts' bullish narrative on a profit turnaround meets some friction here, because:
  • Trailing basic EPS over the last year was a loss of US$4.34, compared with positive basic EPS of US$0.66 in Q1 2026, so the quarterly improvement has not yet shifted the overall loss making profile.
  • Losses have grown at about 59% per year over five years. The forecast of earnings growth of about 71.13% per year therefore has to overcome a very weak recent track record.

On these numbers, bulls are essentially arguing that a business with US$156 million of trailing losses can pivot to strong profitability in a few years. That is a big shift to underwrite. 🐂 Ingevity Bull Case

Price to sales at 2.2x despite revenue softness

• Analysts expect revenue to decline by about 0.4% per year over the next three years, yet the stock trades on a P/S of 2.2x compared with about 1.2x for the wider US Chemicals industry and peers.
• Bears focus on this valuation gap, and the data gives them some backing because:
  • The P/S multiple is roughly 80% higher than peers while the trailing 12 month revenue of US$1.18b and ongoing losses do not point to stronger current fundamentals.
  • Guided revenue slippage, combined with a history of widening losses, sits uneasily with a premium sales multiple. This is exactly the mismatch cautious investors highlight.

For a beginner investor, this is a reminder to look at what you are paying for each dollar of sales and whether the company is already profitable on those sales. 🐻 Ingevity Bear Case

DCF fair value and analyst target send mixed signals

• The DCF fair value in the dataset is US$160.28 per share versus a current share price of US$74.07, while the allowed analyst price target you can compare to here is US$81.75, so the modelled DCF upside is much larger than the upside implied by that analyst target.
• Consensus style thinking that leans on both models and market pricing needs to reconcile a few tensions:
  • At US$74.07, the stock trades at roughly half of the DCF fair value figure, yet only modestly below the US$81.75 analyst target. This suggests different views on how much of the forecast earnings recovery should be reflected today.
  • Those same forecasts assume earnings turn from a loss of US$150.3 million in the recent trailing period to a positive profile over the next few years, so any change to those assumptions could shift both the DCF fair value and analyst targets meaningfully.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Ingevity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all these mixed signals on growth, valuation and risk, do not sit on the fence. Check the data for yourself and weigh up the trade off between upside and downside through the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Ingevity is still working through US$156 million of trailing losses on US$1.18b in revenue, while the stock trades on a premium 2.2x P/S.

If you want ideas where the market price looks more in line with current fundamentals, check out 51 high quality undervalued stocks and compare potential opportunities side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.